

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,521-Conf. #5461
				Filing Date	March 17, 2004
				First Named Inventor	Daniel Wermeling
				Art Unit	1617
				Examiner Name	G. C. Yu
				Attorney Docket Number	INT-002C1CP
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Burstein, <i>et al.</i> , "Intranasal Midazolam Plasma Concentration Profile and its Effect on Anxiety Associated with Dental Procedures", <i>Anesth Prog</i> (1996) 43: pages 52-57.		
	C2	Burstein <i>et al.</i> , "Pharmacokinetics and Pharmacodynamics of Midazolam after Intranasal Administration", <i>J Clin Pharmacol</i> (1997) 37: pages 711-718.		
	C3	Lau, <i>et al.</i> , "Absorption of Diazepam and Lorazepam Following Intranasal Administration", <i>International Journal of Pharmacokinetics</i> , 54 (1989), pages 171-174.		
	C4	Lofsson, <i>et al.</i> , "Cyclodextrin Solubilization of Benzodiazepines: Formulation of Midazolam Nasal Spray", <i>International Journal of Pharmacokinetics</i> , 212 (2001) pages 29-40.		
	C5	Rey, <i>et al.</i> , "Pharmacokinetics of Midazolam in Children: Comparative Study of Intranasal and Intravenous Administration", <i>European Journal of Clinical Pharmacology</i> , (1991) 41: pages 355-357.		
	C6	Walbergh <i>et al.</i> , "Plasma Concentrations of Midazolam in Children Following Intranasal Administration", <i>Anesthesiology</i> , (1991) 74: pages 233-235.		
	C7	Wermeling <i>et al.</i> , "Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration", <i>The Journal of Clinical Pharmacology</i> (2001) 41: pages 1225-1231.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.